Allogeneic Stem Cell Transplantation for Patients With Refractory AML
AML Content Hub
In an interview at the 2021 Annual Meeting of The European Society for Blood and Marrow Transplantation, Mohamad Mohty, MD, PhD, of Saint-Antoine Hospital, Paris, France, discusses the fludarabine-amsacrine-cytarabine (FLAMSA) approach for patients with refractory AML. No treatments are curative for patients with relapsed/refractory AML, but we should not neglect the option of allogeneic stem cell transplantation. Available evidence has demonstrated 30% to 35% leukemia-free survival at 2 years. Professor Mohty notes that we can achieve long-term survival in this subgroup of patients using this approach.
